Lapatinib
Extrahepatic Bile Duct Carcinoma
Floatz Rating
B58/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00107536CT.gov Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | — | Completed | — | — | — |
NCT00101036CT.gov Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Extrahepatic Bile Duct Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lapatinib (this asset) | National Cancer Institute (NCI) | P2 | B · 58 |
| Oxaliplatin | Lisata Therapeutics, Inc. | P3 | BBB |
| Fluorouracilum | Lisata Therapeutics, Inc. | P2 | BBB |
| Capecitabine | National Cancer Institute (NCI) | P3 | BB |
| Irinotecan | AIO-Studien-gGmbH | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Lisata Therapeutics, Inc. | P2 | BB |
| Carboplatin | University of Nebraska | P1/2 | B |
| Escitalopram | Massachusetts General Hospital | P3 | B |
| Epirubicin | University of Nebraska | P1/2 | B |
+38 more in the Extrahepatic Bile Duct Carcinoma cohort
Other indications for Lapatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Male Breast Carcinoma | — | P3 | BB · 67 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Lapatinib in Extrahepatic Bile Duct Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/lapatinib-extrahepatic-bile-duct-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →